CV vs TEM
CV: CapsoVision commercializes AI-powered capsule endoscopy systems with panoramic imaging for small bowel and emerging colon diagnostics, targeting gastroenterologists globally. TEM: Tempus AI leverages genomic sequencing, clinical data aggregation, and machine learning to deliver precision oncology diagnostics and AI-powered treatment recommendations that guide cancer patient care.
Side-by-side fundamentals
| Metric | CV | TEM | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $6.91 | $46.96 | |
| Market cap as of 2026-07-23 | $353M | $8.4B | |
| Net margin as of 2026-07-23 | -198.9% | -22.2% | TEM higher |
| Gross margin as of 2026-07-23 | +51.7% | +63.4% | TEM higher |
| Operating margin as of 2026-07-23 | -200.7% | -20.6% | TEM higher |
| ROE as of 2026-07-23 | -184.2% | -70.2% | TEM higher |
| ROA as of 2026-07-23 | -136.0% | -14.6% | TEM higher |
| Debt / equity as of 2026-07-23 | 0.00 | 2.96 | CV lower |
| Revenue growth (YoY) as of 2026-07-23 | +0.3% | +69.8% | TEM higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +58.3% | |
| Beta as of 2026-07-23 | -1.83 | 2.89 | |
| 1-year return as of 2026-07-22 close | +57.8% | -23.1% | CV higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.